CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Synera (lidocaine 70mg/tetracaine 70mg)drug
Likely dose
Synera (lidocaine 70mg/tetracaine 70mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01744197
NCT01744197Phase 2Completed

Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures

US Oncology Research·interventional·Posted Dec 6, 2012·Updated Oct 25, 2018

In Brief

A Phase 2 clinical trial evaluating Synera (lidocaine 70mg/tetracaine 70mg) for Pain and 2 related conditions. Completed, enrolled 61 participants across 1 site.

Detailed Summary

Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine patch when administered for 30 ± 5 minutes to provide dermal anesthesia in adult oncology patients undergoing venipuncture as part of their care, for treatment or diagnostics (laboratory or imaging). Compared to the use of the placebo patch, this study hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNuvo Research Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 6, 2012
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.6 years ago

Interventions

Synera (lidocaine 70mg/tetracaine 70mg)drug

All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.